Claudia Zampaloni1, Patrizio Mattei2, Konrad Bleicher2,3

  • 1Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.

Nature
|January 3, 2024
PubMed
概括

一种新的性宏环抗生素对抗卡巴耐药的Acinetobacter baumannii (CRAB) 具有强烈的活性. 这种候选药物针对LptB2FGC复合体,为CRAB感染提供了有前途的新疗法.